International Validation of the Immunoscore Biopsy in Patients With Rectal Cancer Managed by a Watch-and-Wait Strategy
Journal of Clinical Oncology · 01.01.2024 · 42 (1) · 70-80
DOI: 10.1200/jco.23.00586 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 01.01.2024. Verfasst von Carine El Sissy und 42 weiteren Autor:innen. Beteiligte Einrichtung: INSERM, Laboratory of Integrative Cancer Immunology, Paris, France. Hauptthemen laut MEDLINE: Watchful Waiting, Rectal Neoplasms. Die Arbeit wurde bisher 56-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
PURPOSE No biomarker capable of improving selection and monitoring of patients with rectal cancer managed by watch-and-wait (W&W) strategy is currently available. Prognostic performance of the Immunoscore biopsy (IS B ) was recently suggested in a preliminary study. METHODS This international validation study included 249 patients with clinical complete response (cCR) managed by W&W strategy. Intratumoral CD3+ and CD8+ T cells were quantified on pretreatment rectal biopsies by digital pathology and converted to IS B . The primary end point was time to recurrence (TTR; the time from the end of neoadjuvant treatment to the date of local regrowth or distant metastasis). Associations between IS B and outcomes were analyzed by stratified Cox regression adjusted for confounders. Immune status of tumor-draining lymph nodes (n = 161) of 17 additional patients treated by neoadjuvant chemoradiotherapy and surgery was investigated by 3'RNA-Seq and immunofluorescence. RESULTS Recurrence-free rates at 5 years were 91.3% (82.4%-100.0%), 62.5% (53.2%-73.3%), and 53.1% (42.4%-66.5%) with IS B High, IS B Intermediate, and IS B Low, respectively (hazard ratio [HR; Low v High], 6.51; 95% CI, 1.99 to 21.28; log-rank P = .0004). IS B was also significantly associated with disease-free survival (log-rank P = .0002), and predicted both local regrowth and distant metastasis. In multivariate analysis, IS B was independent of patient age, sex, tumor location, cT stage (T, primary tumor; c, clinical), cN stage (N, regional lymph node; c, clinical), and was the strongest predictor for TTR (HR [IS B High v Low], 6.93; 95% CI, 2.08 to 23.15; P = .0017). The addition of IS B to a clinical-based model significantly improved the prediction of recurrence. Finally, B-cell proliferation and memory in draining lymph nodes was evidenced in the draining lymph nodes of patients with cCR. CONCLUSION The IS B is validated as a biomarker to predict both local regrowth and distant metastasis, with a gradual scaling of the risk of pejorative outcome.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- INSERM, Laboratory of Integrative Cancer Immunology, Paris, France.
- Equipe Labellisée Ligue Contre le Cancer, Paris, France.
- Cordeliers Research Center, Sorbonne University, University Paris Cité, Paris, France.
- Immunomonitoring Platform, Laboratory of Immunology, Assistance Publique-Hôpitaux de Paris (AP-HP), Georges Pompidou European Hospital, Paris, France.
- Department of Pathology, AP-HP, Georges Pompidou European Hospital, Paris, France.
- Department of Surgery, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
ORCID-Profile: Carine El Sissy, Marine Sroussi, Ana Maria Musina, Maria Gabriela Anitei, Annegien Broeks, Fernando Sanchez Loria, Pierre Laurent-Puig, Aurélien de Reyniès, Mehdi Karoui, David Tougeron, Carlos A Vaccaro, Juan P Santino, Juan Manuel O'Connor, Viorel Scripcariu, Mihail-Gabriel Dimofte, Jean-Pierre Gérard, Myriam Chalabi, Nuno Figueiredo, Rodrigo O Perez, Jérôme Galon, Torben Frøstrup Hansen, Lars Henrik Jensen, Geerard Beets, Franck Pagès
Zitieren
APA
El Sissy, C., Kirilovsky, A., Lagorce Pagès, C., Marliot, F., Custers, P. A., Dizdarevic, E., Sroussi, M., Castillo-Martin, M., Haicheur, N., Dermani, M., Loche, N., Buttard, B., Musina, A. M., Anitei, M. G., van den Berg, J. G., Broeks, A., Iseas, S., Coraglio, M., Loria, F. S., …, & Pagès, F. (2024). International Validation of the Immunoscore Biopsy in Patients With Rectal Cancer Managed by a Watch-and-Wait Strategy. Journal of Clinical Oncology, 42(1), 70-80. https://doi.org/10.1200/jco.23.00586
Vancouver
El Sissy C, Kirilovsky A, Lagorce Pagès C, Marliot F, Custers PA, Dizdarevic E, et al. International Validation of the Immunoscore Biopsy in Patients With Rectal Cancer Managed by a Watch-and-Wait Strategy. Journal of Clinical Oncology. 2024;42(1):70-80. doi:10.1200/jco.23.00586
BibTeX
@article{ElSissy2024,
author = {El Sissy, Carine and Kirilovsky, Amos and Lagorce Pagès, Christine and Marliot, Florence and Custers, Petra A and Dizdarevic, Edina and Sroussi, Marine and Castillo-Martin, Mireia and Haicheur, Nacilla and Dermani, Mohamed and Loche, Nicolas and Buttard, Bénedicte and Musina, Ana Maria and Anitei, Maria Gabriela and van den Berg, José G and Broeks, Annegien and Iseas, Soledad and Coraglio, Mariana and Loria, Fernando Sanchez and Romero, Alfredo and Laurent-Puig, Pierre and de Reyniès, Aurélien and Fernandez, Laura M and Karoui, Mehdi and Tougeron, David and Vaccaro, Carlos A and Santino, Juan P and Poulsen, Laurids Østergaard and Lindebjerg, Jan and O'Connor, Juan Manuel and Scripcariu, Viorel and Dimofte, Mihail-Gabriel and Gérard, Jean-Pierre and Chalabi, Myriam and Figueiredo, Nuno and Perez, Rodrigo O and Habr-Gama, Angelita and Galon, Jérôme and Hansen, Torben Frøstrup and Jensen, Lars Henrik and Beets, Geerard and Zeitoun, Guy and Pagès, Franck},
title = {International Validation of the Immunoscore Biopsy in Patients With Rectal Cancer Managed by a Watch-and-Wait Strategy},
journal = {Journal of Clinical Oncology},
year = {2024},
volume = {42},
number = {1},
pages = {70--80},
doi = {10.1200/jco.23.00586}
}
EUVIMED